Shingles Vaccine Market share, Market trends, and forecasts from 2024 to 2031.

Market Overview and Report Coverage

The Shingles Vaccine Market refers to the market for vaccines that help prevent shingles, a viral infection caused by the varicella-zoster virus. Shingles is a painful rash that mainly affects older adults, and the vaccine is recommended for individuals over the age of 50.
The future outlook for the Shingles Vaccine Market is promising, with a projected growth rate of 15.20% during the forecasted period. Factors driving this growth include an increasing aging population, rising awareness about the importance of preventive healthcare, and advancements in vaccine development technology. Additionally, initiatives by governments and healthcare organizations to promote vaccination and prevent infectious diseases are also expected to fuel market growth.
The current outlook for the Shingles Vaccine Market is positive, as there is a growing demand for vaccines that can prevent shingles and its associated complications. Healthcare providers are increasingly recommending the vaccine to at-risk populations, and manufacturers are investing in research and development to produce more effective and accessible vaccines. Overall, the Shingles Vaccine Market is expected to continue to expand in the coming years as awareness and demand for preventive healthcare measures grow.

Get a Sample PDF of the Report: https://www.reportprime.com/enquiry/request-sample/11825

Market Segmentation
The Shingles Vaccine Market Analysis by types is segmented into:
• Zostavax
• Shingrix

There are two main types of shingles vaccines currently available in the market: Zostavax and Shingrix. Zostavax is a live vaccine that helps prevent shingles in adults 50 years and older. On the other hand, Shingrix is a non-live vaccine that is more effective than Zostavax and is recommended for adults 50 years and older as well. Both vaccines have shown to be effective in reducing the risk of developing shingles and its complications.

Get a Sample PDF of the Report: https://www.reportprime.com/enquiry/request-sample/11825

The Shingles Vaccine Market Industry Research by Application is segmented into:
• Under 50 Years Old
• 50-60 Years Old
• 60-70 Years Old
• Above 70 Years Old

The Shingles vaccine market has applications for different age groups. Under 50 years old, the focus is on individuals with certain medical conditions or at higher risk. In the 50-60 age group, the vaccine is recommended to prevent Shingles and its complications. For those aged 60-70, the vaccine helps reduce the risk of developing the disease. Above 70 years old, the vaccine is crucial in preventing severe cases of Shingles. Overall, the vaccine is essential for preventing Shingles across all age groups.

Purchase this Report:  https://www.reportprime.com/checkout?id=11825&price=3590 

In terms of Region, the Shingles Vaccine Market Players available by Region are:

North America:
• United States
• Canada

Europe:
• Germany
• France
• U.K.
• Italy
• Russia

Asia-Pacific:
• China
• Japan
• South Korea
• India
• Australia
• China Taiwan
• Indonesia
• Thailand
• Malaysia

Latin America:
• Mexico
• Brazil
• Argentina Korea
• Colombia

Middle East & Africa:
• Turkey
• Saudi
• Arabia
• UAE
• Korea


What are the Emerging Trends in the Global Shingles Vaccine market?
Emerging trends in the global shingles vaccine market include an increasing emphasis on prevention and awareness of shingles, leading to a growing demand for vaccines. Advancements in vaccine technologies are also driving innovation in the market, with a focus on creating more effective and convenient vaccine options. Additionally, the rising geriatric population worldwide is expected to boost the market, as older adults are at a higher risk of developing shingles. Furthermore, collaborations between pharmaceutical companies and healthcare organizations to promote vaccination campaigns and improve access to vaccines are likely to shape the future of the shingles vaccine market.

Inquire or Share Your Questions If Any Before Purchasing This Report- https://www.reportprime.com/enquiry/pre-order/11825

Major Market Players
Merck and GlaxoSmithKline are two key players in the competitive shingles vaccine market. Merck, known for its high-quality vaccines, has a long history in the healthcare industry. It was founded in 1891 and has since become a global pharmaceutical company with a focus on vaccines, including the shingles vaccine.
GlaxoSmithKline, another major player in the shingles vaccine market, was formed in 2000 through a merger of Glaxo Wellcome and SmithKline Beecham. The company has a strong presence in the vaccine market and has been a significant player in the development and distribution of the shingles vaccine.
The market for shingles vaccines has been growing steadily in recent years, driven by an aging population and increased awareness of the disease. The global shingles vaccine market size was valued at around $1.6 billion in 2020 and is projected to reach over $2.5 billion by 2027.
In terms of sales revenue, Merck reported total revenue of $51 billion in 2020, with a significant portion coming from its vaccine division. GlaxoSmithKline also reported strong revenues in 2020, totaling $38 billion, with its vaccines segment contributing to a substantial part of the revenue.
Both Merck and GlaxoSmithKline are expected to continue playing a vital role in the shingles vaccine market, with ongoing research and development efforts to improve vaccine efficacy and reach a wider population. The competition between these two companies and other players in the market is expected to drive innovation and advancements in the prevention and treatment of shingles.

Purchase this Report:  https://www.reportprime.com/checkout?id=11825&price=3590
Get a Sample PDF of the Report: https://www.reportprime.com/enquiry/request-sample/11825

Contact Us:
Name: Mahesh Patel
Phone: +1 507 500 7209
Email: sales@reportprime.com

At ReportPrime.com, our vision is to revolutionize the market research industry by delivering unprecedented value to our clients through our audacious goal of providing unparalleled research quality, ethical practices, and affordability. We strive to empower businesses of all sizes with actionable, accurate, and unbiased insights that inform strategic decision-making, drive growth and innovation. We are committed to fostering a culture of excellence, integrity, and transparency, and to fostering lasting partnerships with our clients through affordability and dedicated client servicing.

This release was published on openPR.